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Non-alcoholic fatty liver disease associated with 
hypobetalipoproteinemia: report of three cases and a 
novel mutation in APOB gene
ABSTRACT
Background: Non-alcoholic fatty liver disease, the leading 
cause of chronic liver disease in children, is defined by hepatic 
fat infiltration >5% of hepatocytes, in the absence of excessive 
alcohol intake, evidence of viral, autoimmune or drug-induced 
liver disease. Conditions like rare genetic disorders must be 
considered in the differential diagnosis. 
Case Report: Two male brothers, and a non-related girl, 
all overweight, had liver steatosis. One of the brothers and the 
girl had elevated transaminases; all three presented with low 
total cholesterol, low density lipoproteins and very low density 
lipoproteins cholesterol levels, hypotriglyceridemia and low 
apolipoprotein B. A liver biopsy performed in the brother with 
citolysis confirmed steatohepatitis and the molecular study of 
apolipoprotein B gene showed a novel homozygous mutation 
(c.9353dup p.Asn3118Lysfs17). Patients with cytolysis lost 
weight, however liver steatosis persists. 
Conclusion: Fatty liver disease might be a consequence of 
hypobetalipoproteinemia. Evidence is scarce due to low number 
of reported cases.
Key-words: APOB gene, Children, Familial 
hypobetalipoproteinemia, Non-alcoholic fatty liver disease, Non-
alcoholic steatohepatitis.
FÍGADO GORDO NÃO-ALCOÓLICO ASSOCIADO A 
HIPOBETALIPOPROTEINEMIA: APRESENTAÇÃO DE TRÊS 
CASOS CLÍNICOS E DE UMA NOVA MUTAÇÃO NO GENE 
APOB 
RESUMO
Introdução: O fígado gordo não alcoólico, a principal causa 
de doença hepática crónica na criança, é definida por infiltração 
de gordura hepática em >5% dos hepatócitos, na ausência de 
ingestão alcoólica excessiva, evidência de doença vírica, autoi-
mune ou induzida por drogas. Doenças genéticas raras são con-
dições a considerar no seu diagnóstico diferencial. 
Caso Clínico: Apresentam-se os casos de dois irmãos do 
sexo masculino, e de uma criança do sexo feminino, todos 
com excesso de peso e esteatose hepática. Um dos irmãos e 
a criança do sexo feminino apresentavam também elevação 
das transaminases; todos os casos associados a baixos níveis 
de colesterol total, lipoproteínas de baixa densidade e lipopro-
teínas de muito baixa densidade, hipotrigliceridemia e baixos 
níveis de apolipoproteina B. A biópsia hepática realizada num 
dos irmãos com citólise confirmou a presença de esteatohepa-
tite e o estudo molecular do gene da apolipoproteina B mostrou 
a presença de uma nova mutação em homozigotia (c.9353dup 
p.Asn3118Lysfs17). Os doentes com citólise perderam peso, no 
entanto, a esteatose hepática manteve-se. 
Conclusão: A doença hepática não-alcoólica poderá ser 
uma consequência da hipobetalipoproteinemia. A evidência 
científica é escassa, dado o baixo número de casos descritos.
Palavras-chave: Gene APOB, Criança, Hipobetalipoprotei-
nemia familiar, Fígado gordo não alcoólico, Esteatohepatite não 
alcoólica.
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Abbreviations:
ABL - Abetalipoproteinemia
ALT - Alanine aminotransferase
ApoB - Apolipoprotein B
ANGPTL3 - Angiopoietin- Like 3
ASCAs - Anti-saccharomyces cerevisiae antibodies
AST - Aspartate aminotransferase
BMI p - Percentile of body mass index
CMRD - Chylomicron retention disease
FHBL - Familial hypobetalipoproteinemia
GGT - Gamma-glutamyl transferase
HBL - Hypobetalipoproteinemia
HDL - High density lipoproteins
HLA B51 - Human leukocyte antigen serotype B51
LDL - Low density lipoproteins
MTP - Microsomal triglyceride transfer protein
NAFLD - Non-alcoholic fatty liver disease
NASH - Non-alcoholic steatohepatitis
SAR1B - Secretion Associated, Ras Related GTPase
VLDL - Very low density lipoproteins
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is defined by 
hepatic fat infiltration >5% of hepatocytes in the absence of 
excessive alcohol intake, evidence of viral, autoimmune or drug-
induced liver disease.1-3 A subgroup of patients can also have 
liver cell injury, varying degrees of inflammation (steatohepatitis), 
fibrosis, and cirrhosis.4
The major risk factors for NAFLD are obesity, type 2 
diabetes mellitus and metabolic syndrome2. However, other 
diseases should be considered in the differential diagnosis 
such as hypobetalipoproteinemia, a rare genetic disorder of 
lipid metabolism, in which liver steatosis and increased liver 
transaminases may be associated.5,6 
Hypobetalipoproteinemia (HBL) is characterized by very 
low levels (<5th percentile) of total cholesterol, LDL cholesterol 
or apolipoproteina B (ApoB) in plasma.7 This condition can be 
secondary to vegetarian diets, intestinal fat malabsortion, severe 
liver disease, malnutrition and hyperthyroidism.7 It can also be 
associated with inherited disorders such as abetalipoproteinemia 
(ABL; OMIM 200100) caused by a variety defects in Microsomal 
Triglyceride Transfer Protein (MTP) gene, chylomicron retention 
disease (CMRD; OMIM 246700), caused by Secretion Associated 
Ras Related GTPase 1B (SAR1B) gene mutations, and Familial 
Hypobetalipoproteinemia (FHBL).8-10
FHBL, the most common form of HBL is a genetically 
heterogeneous disorder. Familial hypobetalipoproteinemia 1 
(FHBL1; OMIM 615558) is caused by mutations in APOB gene, 
and familial hypobetalipoproteinemia 2 (FHBL2; OMIM 605019) is 
caused by mutations in Angiopoietin- Like 3 (ANGPTL3) gene.8,9 
The best characterized cases are due to nonsense mutations of 
the APOB gene leading to production of truncated ApoB forms, 
associated with reduced concentrations. There are two forms of 
ApoB, namely ApoB-48, a component of chylomicrons synthesized 
by enterocytes and ApoB-100 a component of VLDL and LDL 
particles synthesized by the liver; these are two isoforms derived 
from differential splicing of RNA from a single APOB gene.6,10 
APOB gene is located on the short arm of human chromosome 2, 
and it consists of 29 exons, of which exon 26, is the largest and 
encodes more than one half of the full-length protein.9
FHBL homozygotes or compound heterozygotes clinical 
features include severe fat malabsorption, neurologic symptoms, 
acanthocytosis, retinitis pigmentosa and/or NAFLD. FHBL 
heterozygotes often have no clinical expression or have fatty 
liver disease.6
Although there seems to be cardiovascular protection in 
these patients, the long-term consequences of fatty liver disease 
are not yet known. We report three cases of NAFLD related to 
FHBL and a novel mutation in the APOB gene.
CASE REPORT
Case 1 
A caucasian 12-year-old male had recurrent oral aphthosis 
with a few years of evolution with recent elevated transaminases 
and steatosis. His parents were nonconsanguineous and his 
8-year-old brother was healthy. 
There was no history of alcohol consumption or drug use. No 
other symptoms were reported such as genital aphthosis, uveitis 
or joint pain. On physical examination he had oral aphthosis, 
mild hepatomegaly, and no other signs of liver disease, nor 
peripheral stigmata of lipidic or endocrine disorders. Neurologic 
and ophthalmologic examinations were normal. Body mass 
index was in percentile 95 (BMI p95).
Complete blood count, blood smear, erythrocyte 
sedimentation rate, electrolytes, creatinine and urea were normal. 
However, he had persistent elevation of transaminases and his lipid 
profile revealed low total cholesterol, LDL-cholesterol and VLDL-
cholesterol levels, hypotriglyceridemia with low apolipoprotein 
(Apo) B levels (Table 1). Abdominal ultrasonography confirmed 
hepatomegaly and moderated steatosis.
Table 1 – Baseline clinical and analytical characteristics of 
FHBL patients
Characteristic Case 1 Case 2 Case 3
Reference 
Interval 
Sex Male Male Female
Age (years) 12 8 9
Body weight (Kg) 60 40 40
BMI percentile (Kg/m2) 95 >95 95
AST (U/l) 61 32 51 10-34
ALT (U/l) 110 29 56 10-44
GGT (U/l) 21 16 26 10-66
Total cholesterol (mg/dl) 58 67 81
LDL-cholesterol (mg/dl) <1 <1 25
HDL- cholesterol (mg/dl) 52 54 47
VLDL-cholesterol (mg/dl) 2,2 ND 9
Triglycerides (mg/dl) 10 <7 44
ApoA (mg/dl) 157 127 125 90-170
ApoB (mg/dl) 35 2 29 56-162
Vitamin A (umol/L) 1,10 N 0,80 1,05-2,79
25-OH-Vitamin D (nmol/L) 120,2 N 59 75-500
Vitamin E (umol/L) 12 Low 10,2 14-23
APOB gene c.9353dup ND 
No abnor-
malities
(p.Asn3118-
Lysfs17)
BMI percentile, percentile of body mass index; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; GGT, gamma-glutamyl transferase; LDL, low density lipoproteins; HDL, high density 
lipoproteins; N, normal, ND, not done, VLDL, very low density lipoproteins; Apo, apolipoprotein
Infectious, autoimmune and metabolic causes of liver disease 
were excluded: hepatitis A, B and C virus were negative; tests for 
anti-nuclear, anti-smooth muscle cell, anti-liver-kidney microsomal 
type 1 antibodies, anti-liver cytosol 1 and anti-soluble liver 
antigen were negative, serum alpha 1-antitrypsin, serum ferritin, 
serum ceruloplasmin and 24-hour urinary copper were normal. 
Autoimmune thyroiditis with normal function and morphology was 
diagnosed. Celiac disease was excluded. He had slightly positive 
anti-Saccharomyces cerevisiae antibodies (ASCAs) and HLA B51. 
The hypothesis of hypobetalipoproteinemia was evocated 
and a lipid profile in both parents and brother was performed. 
Low total cholesterol levels were found in brother and borderline 
values in the father.
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A liver biopsy was performed showing micro and 
macrovesicular steatosis and no features suggesting 
autoimmune disease and liver copper was normal.
The molecular study of APOB gene revealed the novel 
mutation in homozygosity, c.9353dup (p.Asn3118Lysfs17), 
confirming the diagnosis of familial hypobetalipoproteinemia. 
This nonsense mutation has not been reported previously 
and consists of one base pair duplication in c.9353 
position. In addition it was also detected a homozygous 
variant c.8851G>A (p.Glu2951Lys) that has also never been 
described before, and so far is expected to be benign by its 
analysis. 
Fat-soluble vitamins were determined (Table 1) and he 
started vitamin supplementation.
Presently he is asymptomatic, and lost weight (BMI p85), 
however the transaminases remain high and steatohepatitis 
persists on ultrasound. Neurologic and ophthalmologic 
evaluations are normal, without evidence of retinitis 
pigmentosa.
Case 2
This patient is the 8-year-old male brother of case 1. 
He was obese (BMI p>95) with no other significant past medical 
history. He was asymptomatic and his physical examination was 
normal. No hepatomegaly was detected on the examination and 
no signs of liver disease or extrahepatic disease were found. 
Neurologic and ophthalmic examinations had no abnormalities. 
His laboratory tests showed normal hemoglobin levels, as well 
as liver transaminases, electrolytes, creatinine, urea and thyroid 
function. His lipidogram revealed low total cholesterol and LDL-
cholesterol levels, hypotriglyceridemia with low apolipoprotein 
(Apo) B (Table 1). Hepatomegaly and high degree steatosis 
were demonstrated by abdominal ultrasonography. Fat-soluble 
vitamins were determined (Table 1) and he started vitamin E 
supplementation.
He remains asymptomatic, obese (BMI p>95), with normal 
values of transaminases; hepatomegaly and steatosis persists 
on ultrasound. 
The parents of these two patients (case 1 and case 
2) have normal transaminases; liver ultrasound was not 
performed. Although not fulfilling diagnostic criteria for 
hypobetalipoproteinemia, the father´s lipid profile shows 
borderline values of total cholesterol (120 mg/dl), LDL-
cholesterol (59 mg/dl) and triglycerides (35 mg/dl). The mother 
has a normal lipid profile. Until now and due to financial 
constraints, neither case 2 nor both parents performed 
molecular study.
Case 3
A caucasian 9-year-old female had elevated liver 
transaminases. She was overweight (BMI p95), and had no 
history of alcohol consumption or drug use. Her parents were 
nonconsanguineous and healthy, as well as her 16-year-old 
sister. One cousin died at 4 years old with an unknown liver 
disease. 
She was asymptomatic with a normal physical examination. 
No hepatomegaly or splenomegaly were detected, and no other 
clinical signs of liver disease. Neurologic and ophthalmologic 
examination were normal.
Her laboratory tests including complete blood count, blood 
smear, erythrocyte sedimentation rate, electrolytes, creatinine, 
urea and thyroid function tests were normal. Transaminases were 
elevated and her lipid profile showed low total cholesterol, LDL-
cholesterol and VLDL-cholesterol levels, hypotriglyceridemia 
and low apolipoprotein (Apo) B levels (Table 1). Abdominal 
ultrasonography revealed diffuse steatosis.
Hepatitis A, B and C virus were negative; tests for anti-
nuclear, anti-smooth muscle cell, anti-liver-kidney microsomal 
type 1 antibodies, anti-liver cytosol 1 and anti-soluble liver 
antigen were negative; serum alpha 1-antitrypsin, serum ferritin, 
serum ceruloplasmin, 24-hour urinary copper and liver copper 
were normal. Liver biopsy revealed periportal macrovesicular 
steatosis in 30% of hepatocytes.
The diagnosis of hypobetalipoproteinemia was suggested 
and a molecular study of APOB gene showed no mutations in 
the analyzed regions. Her mother and sister´s cholesterol values 
were normal.
Fat-soluble vitamins were determined (Table 1) and she 
started vitamin supplementation.
Currently she remains asymptomatic, with a BMI p75, 
transaminases values are normal, but steatosis persists on 
ultrasound.
DISCUSSION
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic 
steatohepatitis (NASH) have recently emerged as the leading 
cause of chronic liver disease in children, being a reflection 
of the worldwide annual increment of obesity.4 While much of 
these can be explained by traditional risk factors of metabolic 
disease, an important subset is unexplained by these factors 
and require evaluation for secondary causes of NAFLD/NASH4. 
A large set of causes may underlie NAFLD/NASH namely Wilson 
disease, celiac disease, viral and autoimmune hepatitis, diabetes 
mellitus, drugs hepatotoxicity, glycogen storage diseases, 
alfa-1 antitrypsin deficiency, all excluded in our three cases.1,2 
Autoimmune thyroiditis was present in case 1.
The three patients were overweight / obese and this could 
be the cause for NASH per se; however as described above, 
when case 1 lost weight the transaminases values remained high 
and the steatosis persisted, and when case 3 lost weight, the 
transaminases returned to normal but steatosis persisted. These 
features were an indicator of the presence of a cause for NAFLD/
NASH, other than obesity, justifying the need for complementary 
studies.
In case 1, the presence of oral aphthosis, positive ASCAS 
antibodies, and autoimmune thyroiditis made mandatory the 
exclusion of autoimmune liver disease, which was done by 
applying the scoring system for diagnosis of autoimmune 
hepatitis, including liver histology. Another important cause 
of NAFLD/NASH is Wilson disease, excluded by serum 
ceruloplasmin, urinary copper excretion in a 24-hour period, 
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and search for Kayser–Fleischer rings in all patients, and liver 
copper in cases 1 and 3.11,12 Although case 1 and 3 had low 
plasma levels of fat-soluble vitamins, suggesting their intestinal 
malabsorption, none of the patients had delayed growth or 
steatorrhea, therefore it was not considered necessary to 
proceed the study of the intestinal mucosa.
FHBL is a disorder of lipoprotein metabolism characterized 
by decreased levels of ApoB due to mutations in the APOB 
(and other) genes, inducing low levels of cholesterol and 
triglyceride in plasma. These truncated ApoB forms lead to the 
impaired capacity to transport triglycerides from the liver, which 
associated with the low rates of hepatic production of normal 
lipid cause accumulation of triglycerides and other components 
in the liver, contributing to the development of NAFLD/NASH.5
All the three cases fulfilled biochemical criteria for HBL (total 
cholesterol < 100 mg/dl, LDL-cholesterol < 50 mg/dl, ApoB < 50 
mg/dl) and had NAFLD or NASH.
In case 1, the molecular study of APOB gene revealed the 
novel homozygous mutation c.9353dup (p.Asn3118Lysfs17). 
This mutation also leads to a truncated protein, reinforcing the 
idea that it is a disease-causing mutation. Yet, at contrary of 
the previously described mutations, even in homozygosity was 
associated with a slight phenotype. In case 2 the molecular 
study was not performed. In case 3 no mutations were found in 
the analyzed regions of APOB gene. 
The absence of identified mutations can not exclude the 
disease, because mutations outside the analyzed regions of 
the gene or present in other genes, can exist. The majority of 
the cases of FHBL previously described in the literature had 
mutations in the APOB gene resulting in a truncated ApoB, but 
in some cases of FHBL were described mutations in other genes 
(MTP, ANGPTL3). Only about 0.5% of subjects with HBL have 
plasma-detectable ApoB truncations.10,13
Long term consequences of NASH associated with HBL are 
unknown. Therefore, the report of new cases, as well as their 
follow-up, is crucial to the knowledge of the natural history of 
this disease. A remarkable variability was described in the fat 
content of the liver even in FHBL cases caused by the same 
genetic defect and some groups of FHBL patients have no fat 
accumulation in the liver, for still unclear.14
 In conclusion, clinicians should be aware of this disorder, and 
a lipid profile should be assessed in patients with NAFLD/NASH.
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